Trastuzumab is known to downregulate VEGF [73] and can cause hypertension as an adverse effect [74]: the underlying mechanism may therefore be similar to that proposed for PRES caused by anti-VEGF agents. The gene discussed is VEGFA; the disease is Hypertension.